AC Immune
ACIU
44 hedge funds and large institutions have $74.5M invested in AC Immune in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 25 closing their positions.
36% more call options, than puts
Call options by funds: $593K | Put options by funds: $437K
3.6% less ownership
Funds ownership: 24.31% → 20.71% (-3.6%)
31% less funds holding
Funds holding: 64 → 44 (-20)
37% less capital invested
Capital invested by funds: $118M → $74.5M (-$44M)
50% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 20
80% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$9.81M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.5M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$857K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$739K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$480K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.7M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$6.46M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.92M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.66M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.53M |
ACIU Hedge Fund Activity: Q4 2021 in Review
44 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q4 2021, worth a combined $74.5M — down 37% from $118M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ACIU and 5 opened new positions — a net loss of 20 holders — while 20 trimmed existing stakes and 10 added.
The largest buyer was Morgan Stanley, adding an estimated $9.81M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $11.7M sold.
- 44 institutional investors held AC Immune (ACIU) as of Q4 2021, down from 64 in Q3 2021.
- Funds reported $74.5M of AC Immune stock for Q4 2021, down 37% quarter-over-quarter.
- 5 funds opened new AC Immune positions in Q4 2021 and 25 closed out, a net change of -20 holders.
- The largest AC Immune buyer in Q4 2021 was Morgan Stanley, an estimated $9.81M added.
- The largest AC Immune seller in Q4 2021 was Avidity Partners Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q4 2021.